Sign In
Buy AORT
$20.58
+0.160 (+0.784%)
At Close: Jun 03, 2026
Artivion (NYSE:AORT) Shares Gap Down – Should You Sell?
03:49am, Saturday, 04'th Apr 2026
Artivion, Inc. (NYSE: AORT - Get Free Report)'s stock price gapped down prior to trading on Thursday. The stock had previously closed at $36.62, but opened at $33.60. Artivion shares last traded at $3
Artivion, Inc. (NYSE:AORT) Receives Consensus Rating of “Moderate Buy” from Analysts
04:24am, Saturday, 28'th Mar 2026
Shares of Artivion, Inc. (NYSE: AORT - Get Free Report) have received an average rating of "Moderate Buy" from the eight research firms that are presently covering the firm, Marketbeat Ratings reports
Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
04:10pm, Tuesday, 03'rd Mar 2026
ATLANTA, March 3, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate virtually at th
Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript
11:04pm, Thursday, 12'th Feb 2026
Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript
Artivion (AORT) Q4 Earnings Surpass Estimates
06:31pm, Thursday, 12'th Feb 2026
Artivion (AORT) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to break-even earnings per share a year ago.
Artivion Reports Fourth Quarter and Full Year 2025 Financial Results
04:05pm, Thursday, 12'th Feb 2026
Fourth Quarter Highlights: GAAP revenue was $116.0 million in the fourth quarter of 2025 versus $97.3 million in the fourth quarter of 2024. For the full year, GAAP revenue was $441.3 million versus $
Artivion (AORT) to Release Earnings on Thursday
02:52am, Thursday, 05'th Feb 2026
Artivion (NYSE: AORT - Get Free Report) is expected to announce its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect the company to announce earnings of $0.14 per sh
1-Year Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate High Patient Survival with Low Morbidity 2-Year Data from the AMDS PERSEVERE IDE Trial Further Demonstrate the Persistent Clinical Bene
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results
04:05pm, Thursday, 29'th Jan 2026
ATLANTA, Jan. 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter 2025 financial resul
HARBOR CAPITAL ADVISORS, INC. Sells 2 Shares of Artivion Inc (AORT)
01:52pm, Tuesday, 20'th Jan 2026
Summary HARBOR CAPITAL ADVISORS, INC. reduced its stake in Artivion Inc (AORT) by 1.61%, selling 2 shares and holding 122 shares valued at about $10,00
Artivion, Inc. (NYSE:AORT) Receives Average Rating of “Moderate Buy” from Analysts
01:50am, Monday, 12'th Jan 2026
Shares of Artivion, Inc. (NYSE: AORT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the stock, Marketbeat reports. One
Artivion Continues Building Toward Bigger And Better Things
02:04pm, Monday, 29'th Dec 2025
Artivion continues to outperform the med-tech sector, driven by strong execution in stent grafts and On-X valve businesses. Recent clinical updates for the AMDS prosthesis reinforce its safety and eff
Squarepoint Ops LLC Takes $664,000 Position in Artivion, Inc. $AORT
05:10am, Wednesday, 24'th Dec 2025
Squarepoint Ops LLC bought a new position in Artivion, Inc. (NYSE: AORT) during the undefined quarter, according to its most recent filing with the SEC. The institutional investor bought 21,362 shares
Artivion, Inc. (NYSE:AORT) Given Consensus Rating of “Moderate Buy” by Analysts
01:58am, Thursday, 18'th Dec 2025
Artivion, Inc. (NYSE: AORT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine analysts that are presently covering the stock, Marketbeat Ratings reports. One resea
Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?
10:41am, Wednesday, 26'th Nov 2025
Here is how Artivion (AORT) and Pacific Biosciences of California (PACB) have performed compared to their sector so far this year.
